<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075435</url>
  </required_header>
  <id_info>
    <org_study_id>2019P002466</org_study_id>
    <nct_id>NCT04075435</nct_id>
  </id_info>
  <brief_title>Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer's Dementia</brief_title>
  <acronym>CBD</acronym>
  <official_title>Open-Label Trial of a Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer's Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spier Family Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, ten week, clinical trial of a proprietary high CBD/low THC sublingual
      solution (20mg/ml CBD and 0.58mg/ml THC) for the treatment of clinically significant anxiety
      and agitation in mild to moderate Alzheimer's Disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open label trial; all participants will receive active drug.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anxiety Domain on the Neuropsychiatric Inventory-Clinician scale</measure>
    <time_frame>Continuous, weeks 0-10</time_frame>
    <description>Total of clinician impression column on anxiety domain of the NPI-C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total score on the Generalized Anxiety Disorder 7 scale</measure>
    <time_frame>Continuous, week 0-10</time_frame>
    <description>Total score on the Generalized Anxiety Disorder 7 scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety defined by absence of serious adverse events</measure>
    <time_frame>Continuous, weeks 0-10</time_frame>
    <description>Number of serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as defined by lack of treatment emergent cognitive impairment as measured by the Mini Mental Status Exam (MMSE)</measure>
    <time_frame>longitudinal: week 0,10</time_frame>
    <description>Week 10 MMSE total score compared to baseline MMSE total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety defined as absence of treatment emergent delirium as measured by the Confusion Assessment Method (CAM)</measure>
    <time_frame>Continuous, weeks 0-10</time_frame>
    <description>Score on confusion assessment method</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reduction in Agitation Symptoms</measure>
    <time_frame>Continuous, weeks 0-10</time_frame>
    <description>Total clinical impression column score on neuropsychiatric inventory agitation domain (NPI-C)</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in Agitation Symptoms</measure>
    <time_frame>Continuous, weeks 0-10</time_frame>
    <description>Total score of Cohen-Mansfield Inventory (CMAI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in Caregiver Burden</measure>
    <time_frame>Continuous, weeks 0-10</time_frame>
    <description>Total Score of Zarit Caregiver Burden Interview</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Anxiety</condition>
  <condition>Agitation,Psychomotor</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm will include all subjects, who will receive active drug in accordance with the following dosage schedule: for the first week of enrollment, the dose will be 0.5milliliters (mL) of the solution containing 20milligrams/milliliters (mg/mL) CBD and 0.58mg/ml THC twice daily (BID), for a daily total of 20mg CBD and 0.58mg THC. At the Week 1 visit, the dose will be increased to 1.0mL BID, for a daily total of 40mg CBD and 1.16mg THC. At the Week 4 visit, the study physician may increase the dose to 1.5mL BID, for a daily total of 60mg CBD and 1.74mg THC. This higher dose will be used if no clinical improvement is noted with the lower dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high CBD/low THC sublingual solution</intervention_name>
    <description>Coconut oil based solution of 20mg/ml CBD and 0.58mg/ml THC to be administered sublingually.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of probable Alzheimer's Dementia via criteria from McKhann et al.

          2. MMSE score of 15-24 (inclusive)

          3. Clinically significant degree of anxiety, as defined by a Clinical Impression total
             column score of &gt;4 on the Anxiety domain of the NPI-C

          4. A health care proxy available to sign consent on behalf of the participant (if
             applicable)

          5. A caregiver who spends at least 10 hours per week with the subject who is able to
             attend all study visits

          6. Participants and their study partner must be fluent in English

          7. Must be 60-90 years old (inclusive)

        Exclusion Criteria:

          1. Serious or unstable medical illness, including cardiovascular, hepatic, renal,
             respiratory, endocrine, neurologic or hematologic disease, which might confound
             assessment of safety outcomes.

          2. Seizure disorder

          3. Lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, or
             any personality disorder, as determined by the Mini International Neuropsychiatric
             Interview (MINI)

          4. Current episode of major depression, as determined by the MINI

          5. Active substance abuse or dependence within the past 6 months, as determined by the
             MINI

          6. Delirium (as measured by the CAM)

          7. Current inpatient hospitalization

          8. Current regular use of cannabinoid products (&gt;1 use per month)

          9. Positive urine screen for THC at the screening or baseline visit

         10. Allergy to coconut

         11. Participants taking strong inhibitors or inducers of CYP3A4 (e.g. fluconazole,
             fluoxetine, fluvoxamine, ticlopidine, St. John's Wort, etc.), CYP2C19 (ketoconazole,
             erythromycin, etc.), or anti-epileptic drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brent p Forester, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellie Ash, BA</last_name>
    <phone>617-855-2589</phone>
    <email>eash@mclean.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miranda Skurla, BS</last_name>
    <phone>617-855-3272</phone>
    <email>mskurla@mclean.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brent Forester, MD</last_name>
      <phone>617-855-3622</phone>
      <email>bforester@mclean.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Brent P Forester, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Brent Forester</investigator_full_name>
    <investigator_title>Chief, Division of Geriatric Psychiatry</investigator_title>
  </responsible_party>
  <keyword>cannabidiol</keyword>
  <keyword>older adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Behavioral Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

